-

Bruker Demonstrates Novel and Unique Compact 1.0 GHz NMR Magnet

New Innovations Support Customers to Reduce Liquid Helium Consumption

ORLANDO, Fla.--(BUSINESS WIRE)--At the Experimental Nuclear Magnetic Resonance Conference (ENC 2022), Bruker demonstrates a novel and remarkably compact 1.0 GHz NMR magnet, operating at 4.2 Kelvin, for structural biology applications in single-story standard laboratories. Bruker also offers innovations and services for reducing liquid helium consumption.

A major innovation and technology introduction from Bruker is the recent successful factory energization and protein NMR testing of a unique single-story 1.0 GHz 4K NMR magnet, called Ascend Evo 1.0 GHz. Its significantly reduced footprint, weight, and ceiling height requirements, as well as a dramatic threefold reduction in liquid helium consumption provides many more structural biology researchers access to the sensitivity and resolution of GHz NMR. At ENC, Bruker is showing excellent protein 1.0 GHz NMR data from this new and unique technological marvel.

A second innovation is the limited release of the new Heliosmart Recovery solution, a compact, easy-to-site system that can be retrofitted to collect helium gas boil-off from installed NMR magnets. The helium gas is stored in high-pressure cylinders in support of a circular helium economy. The Heliosmart Recovery system can collect the normal boil-off of several NMR magnets, resulting in typical steady-state recovery rates of 80% – 85%. The recovered high-pressure helium gas can be utilized at local or regional helium reliquefaction facilities.

Bruker offers free LabScape Remote Monitoring, which enables our experts to proactively monitor magnets and identify upcoming cryogen refills that can be scheduled well in advance. Bruker also offers helium refills as a service with selected NMR maintenance service agreements.

Dr. Falko Busse, President of the Bruker BioSpin Group, commented: “We are extremely pleased to demonstrate the world’s first single-story 1.0 GHz standard-bore 4 Kelvin NMR magnet, and we are committed to reducing the consumption of liquid helium with our latest innovations.”

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

Contacts

Investor Contact:
Justin Ward
Sr. Director, Investor Relations & Corporate Development
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media Contact:
Thorsten Thiel, Ph. D.
VP of Group Marketing, Bruker BioSpin
T: +49 (721) 5161–6500
E: pr@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Investor Contact:
Justin Ward
Sr. Director, Investor Relations & Corporate Development
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media Contact:
Thorsten Thiel, Ph. D.
VP of Group Marketing, Bruker BioSpin
T: +49 (721) 5161–6500
E: pr@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics with the Launch of CellScape XR

ORLANDO, Fla.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced the launch of CellScape™ XR, a next-generation spatial proteomics platform designed to advance the development of diagnostic and prognostic assays by delivering unprecedented quantitative performance, robustness, and flexibility. CellScape XR addresses a critical bottleneck in translational research by enabling high-throughput, reproducible spatial proteomics at a scale and rigor required for translational and clinical...

Bruker Expands Collaboration with Noetik to Advance Tissue Foundational Models for Translational and Therapeutic Applications

ORLANDO, Fla.--(BUSINESS WIRE)--Bruker Spatial Biology, a division of Bruker Corporation (Nasdaq: BRKR) announced today that it will expand its collaboration with Noetik Inc., following their prior study of more than 3500 patient samples with the CosMx® Spatial Molecular Imager (SMI). CosMx SMI powers Noetik's pre-training and scaling of bio-foundation models to perform complex genome-wide simulations of human cellular- and tissue-level biology to enable diverse therapeutics applications. “Noet...

Bruker Announces Major Advancements at AGBT to Enable Complete High-Fidelity Spatial Biology Across the Biological Spectrum

ORLANDO, Fla.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today significant portfolio advancements from Bruker Spatial Biology to be unveiled at the 2026 Advances in Genome Biology and Technology (AGBT) General Meeting. These updates highlight Bruker’s category leadership in spatial biology and its commitment to delivering best‑in‑class solutions across DNA, RNA, and protein. The Bruker Spatial Biology division will launch several new products, introduce expanded capabilities,...
Back to Newsroom